Capricor extends rally as FDA to review rejected cell therapy
Source: SeekingAlpha
2026-03-10 10:07:55 ET
More on Capricor Therapeutics, Inc.
- Capricor Therapeutics: A High Risk/High Reward Name
- Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript
- Capricor: A Detailed Examination Of Hope-3
- Biotech firm stocks rise on FDA vaccine head’s exit
- Seeking Alpha’s Quant Rating on Capricor Therapeutics, Inc.
Read the full article on Seeking Alpha
For further details see:
Capricor extends rally as FDA to review rejected cell therapy
Capricor Therapeutics Inc.
NASDAQ: CAPR
CAPR Trading
-4.4% G/L:
$32.8588 Last:
892,481 Volume:
$32.50 Open:
CAPR Latest News
March 10, 2026 09:25:00 am
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
March 09, 2026 08:30:00 am
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
February 24, 2026 09:00:00 am
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
January 20, 2026 09:15:00 am
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data
CAPR Stock Data
$1,278,443,622
46,286,693
0.54%
28
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
